bluebird bio (BLUE) is one step closer to potentially obtaining European approval for its gene therapy Zynteglo. That's because the Committee for Medicinal Products for Human Use ((CHMP)) recommended that the gene therapy product should be approved for the European Union. If bluebird gets approval for the gene therapy, that would be a welcomed news for patients. In addition, the biotech is making strides to gain FDA approval in the United States for the very same gene therapy next year.
Positive Regulatory Opinion
The CHMP recommended that Zynteglo should be approved to treat